For the 30-day study, participants were asked to complete several assessments related to mental health symptoms, mood, and cognitive measures. For example, a smartphone finger percussion test has been incorporated into research to measure psychomotor ability, which could be used as a marker for neurodegenerative disorders, including neurodegenerative disorders. including Parkinson’s disease.
That microdose showed more significant improvements in mood, mental health, and psychomotor performance over a month compared with non-traditional counterparts, who completed the same assessments.
Advertisement
Dr. Walsh, who teaches in the Irving K. Barber Department of Arts and Social Sciences, said: “This is the largest longitudinal study of micro-dosing of psilocybin and one of the few to capture the attention of participation of a control group. “Our findings on improving mood and reducing symptoms of depression, anxiety, and stress add to the growing conversation about the therapeutic potential of microdosing.”
Dr. Walsh explains that large doses of psychedelic psilocybin mushrooms have a long history of use among some indigenous people and are prized in Western culture for their hallucinogenic effects. They were also labeled as illegal in the US-led “war on drugs”. But interest has recently expanded from the widespread use of psychedelics — known for producing dramatic changes in mood and consciousness — to the potential therapeutic application of micronutrients. smaller amount. Amounts are so small that they minimally interfere with day-to-day operations.
The Microdose.me project was carried out by an international team that included Dr Pam Kryskow from UBC Vancouver, Maggie Kiraga and Dr Kim Kuypers from Maastricht University in the Netherlands, American theologians Paul Stamets, and Kalin Harvey and Eesmyal Santos-Brault of the Quantified Citizens Health Research Platform.
What is micro-dosing?
Microdosing involves frequent self-administration in doses small enough not to impair normal cognitive function. Amounts can be as small as 0.1 to 0.3 grams of dried mushrooms and can be taken three to five times a week.
The most widely reported substances used for microdosing are the fungus psilocybin and LSD. The psilocybin mushroom is considered non-addictive and relatively non-toxic – especially when compared to tobacco, opioids, and alcohol.
“Our findings on the improvement of mood and mental health associated with microdosing of psilocybin are consistent with previous studies of psychedelic microdose and their supplementation through the use of a study design. Large sample and longitudinal studies allowed us to examine the consistency of the effects across their age, sex, and mental health,” said Rootman.
He explained that comparing small-dose users with no-dosers over the one-month period of the study showed greater improvements in those taking micro-dose when given. Ask about their mood, depression, anxiety, and stress.
Analyzes of the finger test showed that those taking microdosing showed a more positive change in performance than those not taking microdosing, especially in those who did not. over 55 years old.
“Despite the promising nature of these findings, further research is needed to more firmly establish the nature of the relationship between trace dosage, mood and mental health, and the extent to which these effects were due directly to psilocybin instead of Dr. Walsh said participants’ expectations for the substance.
The study was not designed to investigate the potential effect of participant lifespan on micro0dose outcomes, but the authors note that this is a much-needed advance in the field.
“Considering the enormous health costs and prevalence of depression and anxiety, as well as the proportion of patients who are unresponsive to currently available treatments, the potential for an alternative approach,” says Rootman. Others to address these disorders need considerable consideration.
Source: Eurekalert
